Overall survival of CyBorD- and DaraCyBorD-treated patients according to baseline dFLC. Kaplan-Meier curves for OS for patients in the CyBorD (A) or DaraCyBorD (B) cohort, stratified by baseline dFLC levels as indicated. Truncation was applied when fewer than 10 patients remained at risk in each group, reflecting the availability of follow-up data.